Suven Life Sciences gets product patents from Eurasia, Norway
New Delhi: Suven Life Sciences has secured a product patent each from Eurasia and Norway for treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2034 and 2026 respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
Suven Life said the granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson, and Schizophrenia.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd